Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DQ8K3R
|
|||
| Drug Name |
ENV-105
|
|||
| Synonyms |
Carotuximab
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25] | Phase 1 | [1] | |
| Company |
Kairos Pharma Los Angeles, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Endoglin CD105 (ENG) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05401110) IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer. U.S.National Institutes of Health. | |||
| REF 2 | Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells. Front Med (Lausanne). 2022 Sep 7;9:845918. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.